Free Trial

D. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio logo with Medical background

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Tevogen Bio Stock Performance

Shares of NASDAQ TVGN traded down $0.03 during mid-day trading on Tuesday, reaching $1.24. The company's stock had a trading volume of 556,484 shares, compared to its average volume of 5,051,353. Tevogen Bio has a 52 week low of $0.26 and a 52 week high of $3.09. The stock has a fifty day moving average of $1.14 and a two-hundred day moving average of $1.20.

Insiders Place Their Bets

In other news, CEO Ryan H. Saadi sold 1,438,206 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $1.23, for a total value of $1,768,993.38. Following the transaction, the chief executive officer now owns 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. The trade was a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 73.24% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tevogen Bio

Several institutional investors have recently bought and sold shares of TVGN. Geode Capital Management LLC boosted its holdings in shares of Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock valued at $465,000 after purchasing an additional 107,566 shares during the last quarter. Northern Trust Corp raised its stake in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after purchasing an additional 13,595 shares in the last quarter. Nuveen LLC purchased a new stake in Tevogen Bio during the first quarter valued at $97,000. XTX Topco Ltd purchased a new position in shares of Tevogen Bio in the 4th quarter worth $55,000. Finally, Barclays PLC increased its holdings in shares of Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after buying an additional 12,847 shares during the last quarter.

Tevogen Bio Company Profile

(Get Free Report)

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

Featured Articles

Should You Invest $1,000 in Semper Paratus Acquisition Right Now?

Before you consider Semper Paratus Acquisition, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Semper Paratus Acquisition wasn't on the list.

While Semper Paratus Acquisition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in July 2025
3 Defense Stocks Under $10 With Massive Upside
NVIDIA: Another 200% Growth Ahead? (PLUS 2 Companies Riding Along)

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines